Advantage Alpha Capital Partners LP Sells 14,350 Shares of Encompass Health Co. (NYSE:EHC)

Advantage Alpha Capital Partners LP lessened its stake in shares of Encompass Health Co. (NYSE:EHC) by 16.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 75,435 shares of the company’s stock after selling 14,350 shares during the period. Encompass Health accounts for about 1.7% of Advantage Alpha Capital Partners LP’s portfolio, making the stock its 8th biggest position. Advantage Alpha Capital Partners LP owned about 0.07% of Encompass Health worth $7,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently modified their holdings of EHC. Magnetar Financial LLC lifted its stake in Encompass Health by 1,176.6% during the second quarter. Magnetar Financial LLC now owns 744,836 shares of the company’s stock worth $63,899,000 after purchasing an additional 814,018 shares during the last quarter. Thrivent Financial for Lutherans boosted its stake in Encompass Health by 2,302.7% in the second quarter. Thrivent Financial for Lutherans now owns 603,558 shares of the company’s stock valued at $51,780,000 after buying an additional 578,438 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Encompass Health by 614.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 540,519 shares of the company’s stock valued at $44,637,000 after acquiring an additional 464,897 shares during the last quarter. AQR Capital Management LLC raised its stake in Encompass Health by 213.3% during the second quarter. AQR Capital Management LLC now owns 207,202 shares of the company’s stock worth $17,776,000 after acquiring an additional 141,075 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Encompass Health by 762.4% in the second quarter. Cubist Systematic Strategies LLC now owns 83,347 shares of the company’s stock worth $7,150,000 after acquiring an additional 73,683 shares during the last quarter. 97.25% of the stock is currently owned by institutional investors.

Encompass Health Price Performance

EHC stock opened at $102.00 on Tuesday. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The company’s fifty day simple moving average is $97.28 and its 200 day simple moving average is $90.99. Encompass Health Co. has a 12-month low of $63.78 and a 12-month high of $104.55. The firm has a market cap of $10.28 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 1.34 and a beta of 0.88.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.09. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.33 billion. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The firm’s revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.86 EPS. On average, analysts expect that Encompass Health Co. will post 4.29 earnings per share for the current year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Thursday, January 2nd will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Thursday, January 2nd. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.67%. Encompass Health’s dividend payout ratio (DPR) is presently 16.43%.

Analyst Ratings Changes

Several brokerages recently issued reports on EHC. Barclays lifted their price target on shares of Encompass Health from $109.00 to $116.00 and gave the company an “overweight” rating in a report on Tuesday, October 29th. KeyCorp upped their price objective on Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research note on Tuesday, October 29th. Truist Financial reissued a “buy” rating and set a $116.00 target price (up from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. UBS Group upped their price target on shares of Encompass Health from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Finally, Royal Bank of Canada lifted their price target on shares of Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Nine analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $107.11.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.